Global Neurology Clinical Trials Market Report and Forecast 2025-2034

Neurology Clinical Trials Market Overview

Neurology clinical trials are research studies that evaluate the safety and effectiveness of treatments for disorders affecting the brain, spinal cord, and nervous system. These trials test new drugs, devices, or interventions for conditions like Alzheimer’s, Parkinson’s, epilepsy, and multiple sclerosis. Conducted in phases, they involve patient volunteers and follow strict regulatory guidelines to ensure ethical standards and accurate data. Advances in imaging, biomarkers, and digital tools are improving trial outcomes. Neurology trials are vital for developing innovative therapies and understanding complex neurological diseases that impact millions worldwide.

Neurology Clinical Trials Market Growth Drivers

Surge in FDA Approvals Based on Trial Outcomes Impacting the Market Value

Growing global stroke prevalence and increasing demand for faster, more effective thrombolytic therapies are major drivers of market growth in neurology clinical trials. For instance, in March  2025, the US FDA approved a fast-acting thrombolytic agent for acute ischaemic stroke, following favourable results from the 1,600-patient AcT trial and corroborating findings from the TRACE-2 study in China. The new agent demonstrated similar safety and efficacy compared to the standard therapy, while offering a significantly quicker administration time. This regulatory milestone is poised to expand clinical trial activity for stroke therapies and thrombectomy-combination approaches, further enhancing market value by fostering drug development for time-sensitive neurological emergencies.

Increasing Focus on Addressing Unmet Needs to Elevate Neurology Clinical Trials Market Demand

Rising awareness of patient-centric care and the growing need for gender-specific treatment guidance is strengthening the focus of neurology clinical trials. For instance, at the American Epilepsy Society Meeting in December 2024, new data highlighted significant gaps in epilepsy care for women of childbearing age. The study found that access to timely, accurate, and relevant treatment information remains limited, particularly regarding pregnancy and epilepsy. This contributes to confusion, anxiety, and a lack of informed decision-making. These findings underscore the urgency of inclusive and targeted clinical epilepsy research. Consequently, future neurology trials are expected to incorporate diverse patient perspectives, leading to the development of more accessible, tailored therapies and enhancing global market value.

Neurology Clinical Trials Market Trends

Neurology Clinical Trials Market Segmentation

Neurology Clinical Trials Market Share

Phase III Trials to Lead the Segmentation by Type

Phase III is expected to hold the largest market share in the segment by type. This is attributed to the high number of participants, longer trial durations, and critical role in confirming treatment efficacy and monitoring adverse effects before regulatory approval. Neurological conditions like stroke and Alzheimer’s require large-scale, evidence-based validation, making Phase III trials a priority. Increasing R&D investment, particularly from pharmaceutical giants, and growing demand for advanced neurological treatments will further boost this segment. In the forecast period, the rising pipeline of neurology drugs is poised to fuel significant growth in Phase III trials.

Stroke to Hold a Significant Neurology Clinical Trials Market Value for Segmentation by Indication

Stroke is projected to dominate the market by indication, owing to its high global prevalence and status as a leading cause of long-term disability. As per the analysis by Expert Market Research, the ischemic stroke market is expected to grow at a CAGR of 5.2% during the forecast period of 2025-2034.  The urgent need for effective stroke therapies has prompted increased research funding and accelerated development of both acute and post-stroke care solutions. Advancements in drug delivery, thrombectomy procedures, and neuroprotective agents are contributing to heightened clinical activity. With regulatory bodies supporting innovation in this area and new therapeutic agents progressing through the pipeline, stroke-related trials will continue to drive market growth significantly over the coming years, reinforcing this segment’s leadership position.

Interventional Studies to Dominate the Share by Study Design

Interventional studies are set to lead the market by study design due to their direct focus on evaluating treatment efficacy through controlled environments. These trials enable precise measurement of drug impact, safety, and long-term outcomes, which is essential in complex neurological disorders. The growing need for innovative therapies in stroke, Alzheimer’s, and epilepsy is pushing sponsors to adopt interventional designs. Additionally, regulatory incentives and technological advancements in patient monitoring and biomarker integration are streamlining such trials. As more novel interventions enter the clinical phase, this segment is likely to witness sustained dominance and market value expansion.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Neurology Clinical Trials Market Analysis by Region

North America is likely to hold the largest market share, driven by strong regulatory frameworks, advanced research infrastructure, and a high burden of neurological disorders. For instance, in February  2024, the U.S. FDA approved Kisunla (donanemab-azbt) for early-stage Alzheimer’s treatment following successful trials showing statistically significant improvements across multiple cognitive and functional measures. This milestone reflects the region’s robust clinical ecosystem and readiness to support late-stage, large-scale neurology trials. Meanwhile, Europe is progressing steadily with collaborative academic studies, while Asia-Pacific is gaining traction through increased investment and trial decentralisation. However, North America’s consistent innovation pipeline cements its leading role in market development.

Leading Players in the Neurology Clinical Trials Market

Other key players in the market include Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., and Annovis Bio. 

Key Questions Answered in the Neurology Clinical Trials Market

• What was the global neurology clinical trials market value in 2024? 
• What is the global neurology clinical trials market forecast outlook for 2025-2034?
• What is market segmentation based on type?
• What is market segmentation based on indication?
• What is market segmentation based on study design?
• What are the major factors aiding the global neurology clinical trials market demand?  
• How has the market performed so far, and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?
• What are the major global neurology clinical trials market trends?
• Which type will lead the market segment?  
• Which indication will lead the market segment?  
• Which study design will lead the market segment?  
• Who are the key players involved in the global neurology clinical trials market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?